Ascendis Pharma to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
07 Junho 2023 - 9:30AM
Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan
Mikkelsen, President & Chief Executive Officer, and Scott
Smith, Executive Vice President & Chief Financial Officer, will
participate in a fireside chat at the Goldman Sachs 44th Annual
Global Healthcare Conference on Tuesday, June 13.
Details:
Event |
Goldman Sachs 44th Annual Global Healthcare Conference |
Location |
Dana Point, CA |
Date |
Tuesday, June 13, 2023 |
Time |
12:20 p.m. Eastern Time / 9:20 a.m. Pacific Time |
A live webcast of the event will be available via the Investors
& News section of the Ascendis Pharma website at
https://investors.ascendispharma.com. A webcast replay will also be
available on this website shortly after conclusion of the event for
30 days.
About Ascendis Pharma A/SAscendis Pharma is
applying its innovative TransCon platform to build a leading, fully
integrated, global biopharma company focused on making a meaningful
difference in patients’ lives. Guided by its core values of
patients, science and passion, the company uses its TransCon
technologies to create new and potentially best-in-class therapies.
Ascendis is headquartered in Copenhagen, Denmark, and has
additional facilities in Heidelberg, Berlin and Munich, Germany;
Palo Alto and Redwood City, California; and Princeton, New Jersey.
Please visit www.ascendispharma.com to learn more.
Forward-Looking Statements This press release
contains forward-looking statements that involve substantial risks
and uncertainties. All statements, other than statements of
historical facts, included in this press release regarding
Ascendis’ future operations, plans and objectives of management are
forward-looking statements. Examples of such statements include,
but are not limited to, statements relating to (i) Ascendis’
ability to apply its TransCon platform to build a leading, fully
integrated, global biopharma company, and (ii) Ascendis’ use of its
TransCon technologies to create new and potentially best-in-class
therapies. Ascendis may not actually achieve the plans, carry out
the intentions or meet the expectations or projections disclosed in
the forward-looking statements and you should not place undue
reliance on these forward-looking statements. Actual results or
events could differ materially from the plans, intentions,
expectations and projections disclosed in the forward-looking
statements. Various important factors could cause actual results or
events to differ materially from the forward-looking statements
that Ascendis makes, including the following: dependence on third
party manufacturers, distributors and service providers for
Ascendis’ products and product candidates; unforeseen safety or
efficacy results in its development programs or on-market products;
unforeseen expenses related to commercialization of any approved
Ascendis products; unforeseen expenses related to Ascendis’
development programs; unforeseen selling, general and
administrative expenses, other research and development expenses
and Ascendis’ business generally; delays in the development of its
programs related to manufacturing, regulatory requirements, speed
of patient recruitment or other unforeseen delays; Ascendis’
ability to obtain additional funding, if needed, to support its
business activities; the impact of international economic,
political, legal, compliance, social and business factors,
including inflation, and the effects on its business from the
worldwide COVID-19 pandemic and ongoing conflicts such as that in
the region surrounding Ukraine and Russia. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking
statements, as well as risks relating to Ascendis’ business in
general, see Ascendis’ Annual Report on Form 20-F filed with the
U.S. Securities and Exchange Commission (SEC) on February 16, 2023
and Ascendis’ other future reports filed with, or submitted to, the
SEC. Forward-looking statements do not reflect the potential impact
of any future licensing, collaborations, acquisitions, mergers,
dispositions, joint ventures, or investments that Ascendis may
enter into or make. Ascendis does not assume any obligation to
update any forward-looking statements, except as required by
law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company
logo and TransCon are trademarks owned by the Ascendis Pharma
group. © June 2023 Ascendis Pharma A/S.
Investor Contacts: |
|
|
Media Contact: |
Tim Lee |
|
|
Melinda Baker |
Ascendis Pharma |
|
|
Ascendis Pharma |
+1 (650) 374-6343 |
|
|
+1 (650) 709-8875 |
tle@ascendispharma.com |
|
|
media@ascendispharma.com |
ir@ascendispharma.com |
|
|
|
|
|
|
|
Patti Bank |
|
|
|
ICR Westwicke |
|
|
|
+1 (415) 513-1284 |
|
|
|
patti.bank@westwicke.com |
|
|
|
Ascendis Pharma AS (NASDAQ:ASND)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Ascendis Pharma AS (NASDAQ:ASND)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024